-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the journal Oncologist published the results of a phase II clinical study evaluating the use of the PD-1 inhibitor pembrolizumab (pembrolizumab) in combination with CAPOX (oxaliplatin + capecitabine) in advanced cholangiocarcinoma (BTC).
Efficacy and safety of treatment
.
Efficacy and safety of treatment
.
The patients studied were histologically confirmed BTC, pembrolizumab + oxaliplatin d1, capecitabine bid d1-d14 for 6 cycles
.
The patients studied were histologically confirmed BTC, pembrolizumab + oxaliplatin d1, capecitabine bid d1-d14 for 6 cycles
The study included 11 patients, with a median age of 67 years (51-81 years), and 55% of patients were women
PD patients received an average of 5.
The median progression-free survival was 4.
1 months (95% CI: 2.
The median progression-free survival was 4.
The most common grade 3 and 4 adverse events were decreased lymphocyte count (64%), anemia (36%), decreased platelet count (27%), and hyponatremia (27%)
.
The most common grade 3 and 4 adverse events were decreased lymphocyte count (64%), anemia (36%), decreased platelet count (27%), and hyponatremia (27%)
In conclusion, the study shows that capecitabine + oxaliplatin combined with pembrolizumab is tolerable and is a potentially effective treatment for refractory advanced BTC
.
In conclusion, the study shows that capecitabine + oxaliplatin combined with pembrolizumab is tolerable and is a potentially effective treatment for refractory advanced BTC
Original source:
Cecilia Monge, Erica C.
Pehrsson, Changqing Xie, et al.
Cecilia Monge, Erica C.
Pehrsson, Changqing Xie, et al.
A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.
The Oncologist, 2022, 27, e273–e285.
https: https://doi.
org/10.
1093/oncolo/oyab073 .
https://doi.
org/10.
1093/oncolo/oyab073 https://doi.
org/10.
1093/oncolo/oyab073 .
.
Leave a comment here